Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SP140 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SP140 (Bromodomain/PHD) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SP140 Products |
| Gene Delivery | SP140 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SP140 Products |
| Benchmark Ab | Anti-SP140 Recombinant Antibody Recombinant positive control for assay validation. |
View SP140 Products |
| Validator | SP140 siRNA Set For knockdown verification. |
View SP140 Products |
| Related Target A | SP100 Subfamily off-target counter-screening. |
View SP100 Products |
| Related Target B | SP110 Subfamily off-target counter-screening. |
View SP110 Products |
| Related Target C | BRD4 Pan-bromodomain selectivity profiling. |
View BRD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily off-target counter screening | Homolog panel proteins (SP100, SP110) strictly verified by mass spectrometry and sequence alignment. |
| Pan-bromodomain selectivity profiling | Active BRD4 and other BET family proteins available with high purity (>95%). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and reference antibodies included |
| False Positives | Validated siRNA included for target knockdown and specificity checks |
Live SP140 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SP140 therapeutics is intensifying, with major players shifting focus from traditional epigenetic modulators to highly selective small molecule inhibitors and PROTACs targeting the SP140 bromodomain. As first-generation therapies reach the clinic, the next wave of R&D is targeting Crohn's disease, ulcerative colitis, and chronic lymphocytic leukemia (CLL).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | GSK (GSK761) | Crohn's Disease, IBD | Selectivity Assay (Need Mutant vs WT SP140 Bromodomain Proteins) |
| PROTACs / Degraders | Academic / Biotech Consortia | Inflammation, CLL | Ubiquitination & Degradation Assay (Need High-Purity SP140 & Lentivirus) |
| Gene Therapy / Editing | Preclinical Startups | Autoimmune Diseases | Stable Overexpression Validation (Need Lentivirus Premade Particles) |